🎤 Upcoming Biotech Conferences
Earnings Calendar
Upcoming biotech earnings with each company's cash runway and dilution risk from SEC filings: see who may need to raise money after the report. Reported EPS comes from the company's 10-Q.
Biotech earnings reports reveal cash burn rate, runway, and revenue trajectory. Unlike tech stocks where EPS drives price, biotech earnings matter for different reasons: cash position (can they fund trials?), revenue from approved drugs (commercial traction), and management guidance on pipeline milestones.
Pre-revenue biotechs with declining cash often do offerings near earnings, causing dilution. Revenue-stage biotechs can gap +20% on strong drug sales or -15% on disappointing adoption. The earnings call itself often contains critical pipeline updates.
EPS estimates: analyst consensus. EPS actual: basic EPS for the quarter from the company's 10-Q on SEC EDGAR (click a figure for the filing); fourth quarters are reported for the full year in the 10-K and stay empty. Cash runway and dilution risk: Dilution Watch, from cash, burn and financing filings on SEC EDGAR; ATM = an at-the-market offering program on file.